Anteris Technologies Global Corp. (AVR)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$9.04+3.67%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
Intact: The reason to own it still holds.
Anteris is working to stop costly development with v2vmedtech. It leased new office and warehouse space. The company aims to grow revenue above $19 million next year. The stock price rose over 90% in the last 63 days.
The company is still losing money with negative earnings. Revenue growth is uncertain. The recent stop of development with v2vmedtech may hurt future prospects.
The market values Anteris at about $3.72 per share. This price reflects high growth hopes but the company is still unprofitable. Our fair value matches the current price, showing limited upside.
Breaks if: Debt covenant breach or liquidity shortfall after debt issuance
Breaks if: Failure to utilize leased space or lease termination
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth bet. The company is currently experiencing losses and has a mixed management execution record, which adds uncertainty to its future performance.
The market appears to be pricing in a high level of fragility due to AVR's expensive valuation compared to peers, despite its recent weak performance. There is a significant premium compared to its industry cohort, indicating that expectations may be high relative to the current fundamentals.
Fundamentals are likely to remain under pressure in the near term, especially given the elevated risk of missing earnings again. Recent results have shown weak financial performance, and management's execution on key priorities is mixed.
The long-term thesis hinges on the outcomes of the PARADIGM Trial for DurAVR THV and the performance of sector bellwethers like ABT, MDT, and SYK. Positive momentum in the healthcare sector could support AVR, while any downturn in these bellwethers could negatively impact the company.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Resumption of development contributions with v2vmedtech or increased related costs
Breaks if: Revenue falls below $13.9 million in FY26 or fails to grow toward $19.9 million in FY27
In the next 1 to 3 years, AVR's performance will depend on its ability to execute on trials and navigate sector dynamics. Not investment advice.